Britain’s pharmaceutical industry is appealing to Boris Johnson to strike a swift side-deal with Brussels to avoid delays and shortages of medicines if he crashes the UK out of the EU in a no-deal Brexit at the end of this year.
The prime minister’s announcement on Friday that he was preparing for no deal on 31 December has left the industry without the agreement on mutual recognition of standards needed to avoid hugely costly duplication of red tape and maintain the flow of trade in vital drugs.
With less than 75 days to go until the transition to post-Brexit relations with Europe, the Association of the British Pharmaceutical Industry (ABPI) says that failure to secure either an overarching trade deal or a sector-specific agreement would cost “many, many millions” of pounds and introduce delays of up to six weeks in supplies.
To read the full article, click here